New Horizons in Pustular Psoriasis: Will You Be Ready?

CME: 0.5

May 19, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Program Overview

Clinicians must be ready to translate rapidly evolving guidance and emerging science to improve outcomes for their patients. Dr. Mark Lebwohl from the Icahn School of Medicine at Mount Sinai recently hosted several small-group CME Meet-Up’s. This recorded meet-up discusses:

  • the lack of U.S. guidance that complicates diagnosis and disease assessment
  • the most recent pathophysiologic findings for pustular psoriasis and implications for treatment
  • the latest safety and efficacy data for new and emerging agents for pustular psoriasis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess patients with pustular psoriasis, based on clinical manifestations, diagnostic criteria, and disease severity.
  • Discuss the pathophysiology of pustular psoriasis, including how it differs from that of plaque psoriasis and potential pathways for therapeutic targets.
  • Review the clinical profiles and mechanisms of action of new and emerging biologic treatment options for adults with PPP and GPP.

Post a comment to this article